APi Group is evolving into a platform with a defensible, recurring revenue mix, driven by regulation-based Safety Services and growing Specialty Services exposure. APG's Q2 2025 results showed stro...

APi (APG) could produce exceptional returns because of its solid growth attributes.

APi Group Corporation (NYSE:APG ) Q2 2025 Earnings Conference Call July 31, 2025 8:30 AM ET Company Participants Adam Fee - Vice President of Investor Relations Glenn David Jackola - Executive VP &...

APi (APG) is well positioned to outperform the market, as it exhibits above-average growth in financials.

Apogee Therapeutics, Inc.'s APG777 shows best-in-class week-16 efficacy and quarterly/semi-annual dosing potential. In my view, this could give this drug candidate a great competitive profile. In f...

APEX Part A met all primary and key secondary endpoints and exceeded trial objectives, including 7 1.0% decrease  from baseline in EASI at Week 16

SAN FRANCISCO and BOSTON, July 06, 2025 (GLOBE NEWSWIRE) -- Apogee Therapeutics, Inc., (Nasdaq: APGE), a clinical-stage biotechnology company advancing novel biologics with the potential for differ...

APi (APG) possesses solid growth attributes, which could help it handily outperform the market.

Multiple doses of APG808 resulted in rapid suppression of FeNO, a biomarker of Type 2 inflammation associated with exacerbations in asthma, with a robust maximal FeNO decrease from baseline of 53%

APi Group Corporation (NYSE:APG ) Q1 2025 Earnings Conference Call May 1, 2025 8:30 AM ET Company Participants Adam Fee – Vice President of Investor Relations Russ Becker – President and Chief Exec...

ATLANTA--(BUSINESS WIRE)--Oldcastle APG, the leading provider of outdoor living solutions in North America, will share its latest product innovations and solutions at the 2025 NAHB International Bu...

I reiterate a buy rating for APG due to strong market share potential, growth acceleration, and adj EBITDA margin expansion prospects for FY25 and beyond. APG's solid demand trend is evidenced by a...

APi Group Corporation (NYSE:APG ) Q3 2024 Earnings Conference Call October 31, 2024 8:30 AM ET Company Participants Adam Fee - VP, IR Russell Becker - President and CEO Kevin Krumm - EVP and CFO Co...

APi Group Corporation's earnings are set to grow in Q3 and Q4 2024, despite a recent decline in share price, presenting a Strong Buy opportunity. The company's 13/60/80 framework aims to boost adju...

Continued advancement of pipeline and execution towards expected milestones, including APG777 16-week proof-of-concept data from the Phase 2 Part A trial in 2H 2025, APG808 interim Phase 1 data in ...